Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Recruiting in Palo Alto (17 mi)
+134 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Bristol-Myers Squibb
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study it to evaluate the long-term safety and tolerability of BMS-820836 in patients with depression.
Research Team
BS
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
Inclusion Criteria
Men and women of age 18-65 years (Argentina the minimum age will be 24 years of age)
Patients randomized in parent study who complete CN162-006 and CN162-007 who consent to enter the rollover study.
Patient not randomized in parent study that meet inadequate response criteria
Treatment Details
Interventions
- BMS-820836 (Antidepressant)
Participant Groups
3Treatment groups
Experimental Treatment
Group I: Arm 3: Placebo + BMS-820836 (2 mg/day)Experimental Treatment2 Interventions
Group II: Arm 2: Placebo + BMS-820836 (1 mg/day)Experimental Treatment2 Interventions
Group III: Arm 1: Placebo + BMS-820836 (0.5 mg/day)Experimental Treatment2 Interventions
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Trials
2,731
Recruited
4,127,000+
Headquarters
New York City, USA
Known For
Oncology & Cardiovascular
Top Products
Eliquis, Opdivo, Revlimid, Orencia
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania